Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 113

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 113
---
 selected candidate, including GLP toxicology and 
 safety pharmacology studies in accordance with FDA guidelines.                                                                      |

| 3. | Develop clinical study                                                                                                                 
 protocol and prepare a standard IND submission for the chosen indication, with the goal of initiating a Phase 1 clinical trial focused 
 on safety and immunogenicity in healthy volunteers.                                                                                    |

Contingent R&D Milestones (12–24 months):

| Milestone                                                  |     | Target Timeline |
| Final report of challenge/POC studies (SARS-CoV-2 and WNV) |     | Q1 2026         |
| Internal review and candidate prioritization               |     | Q2 2026         |
| IND-enabling GLP studies initiation                        |     | Q3 2026-Q3 2027 |
| GMP manufacturing + Pre-IND submission (standard pathway)  |     | Q3-Q4 2027      |
| Phase 1 trial initiation (pending IND clearance)           |     | Q2 2028         |

Yissum Research and License Agreements

Our rights to the foregoing are based on research
and license agreement with Yissum, the tech transfer company of the Hebrew University in Jerusalem. Below is a summary of the principal
terms of these agreements.

On November 24, 2022, LipoVation entered into
the Yissum Agreements, which were subsequently amended. Pursuant to the Yissum License Agreements, Yissum granted LipoVation an exclusive,
worldwide, sublicensable license to develop, have developed, manufacture, have manufactured, use, market, distribute, export, import
and/or sell products and/or processes that comprise, contain or incorporate certain technology relating to the Nanoparticles-based liposomal
therapeutics, including the above noted patents (the “Licensed Patents”). Under the terms of the Yissum Agreements, Yissum
retains the ownership of the Licensed Technology (as such term is defined therein). All rights in the results of the activities carried
out by LipoVation or third parties in the development of these products shall be solely owned by LipoVation (unless an employee of the
Hebrew University of Jerusalem or each of its branches is an inventor of any of the patents claiming such results, in which case they
shall be owned jointly by Yissum and LipoVation). LipoVation m has the right to grant sub-licenses to third parties in accordance